A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.

Trial Details

NCT ID
NCT07139873
Phase
PHASE3
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • DZD8586
  • Bendamustine
  • Idelalisib
  • Rituximab
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Male and female participants ≥ 18 years of age.
  • ECOG performance status 0-2.
  • Confirmed diagnosis of relapsed or refractory CLL/SLL with indication for treatment.
  • Adequate bone marrow reserve and organ system functions.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →